The Russian Competition Authority investigates whether a pharmaceutical company with dominant position in wholesale of certain generics unreasonably refused to conclude contract for medicine supply (Ipsen / Biotek)

FAS Russia: Ipsen Unreasonably Refused Biotek to Conclude Contract for Medicine Supply* In order not to enter into a contract with a counterparty the pharmaceutical company has repeatedly changed its commercial policy during the review of the distributor's application. The FAS Russia issued a warning to the pharmaceutical company Ipsen to stop actions that contain signs of violation of the Law on Protection of Competition. Thus, having no economic and technological

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

Citation

Russian Competition Authority, The Russian Competition Authority investigates whether a pharmaceutical company with dominant position in wholesale of certain generics unreasonably refused to conclude contract for medicine supply (Ipsen / Biotek), 5 octobre 2020, e-Competitions October 2020 - II, Art. N° 97190

Visites 62

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues